Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cosopt
timolol/dorzolamide combination · 1 trial · 1 indication
The therapeutic goal of normal tension glaucoma treatment includes lowering IOP to prevent progression of damage in optic nerves or vision. In this trial, IOP was measured with the same tonometer throughout the study. A decreased IOP from baseline is considered an improvement. IOP was measured in both eyes and the eye with the higher IOP was used for the participant.
| Arm | Type | Description |
|---|---|---|
| Timolol/Dorzolamide | EXPERIMENTAL | Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks |
| Name | Type | Description |
|---|---|---|
| timolol/dorzolamide combination | DRUG | Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks |
Inclusion Criteria: * Patients who have not been treated with a glaucoma medication within 6 weeks prior to study participation after diagnosis with primary open-angle glaucoma * Patients with primary open-angle glaucoma based on gonioscopy * Patients with normal tension glaucoma diagnosed based on...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Timolol/dorzolamide combination is a small molecule ophthalmic product developed by Merck & Company, Inc. (ticker MRK) for glaucoma. It combines timolol maleate with dorzolamide and has been studied in a Phase 2 trial in patients with normal tension glaucoma. It is an investigational combination rather than a newly approved product.
Timolol/dorzolamide combination includes timolol, which acts as an antagonist at the beta-adrenergic receptors ADRB1 and ADRB2. By blocking these receptors, timolol reduces aqueous humor production in the eye. The dorzolamide component is a carbonic anhydrase inhibitor that also lowers aqueous humor formation, so the combination targets two pathways that reduce intraocular pressure in glaucoma.
Merck & Company, Inc., which trades under the ticker MRK, is the developer of the timolol/dorzolamide combination. The company sponsored the clinical program evaluating this fixed combination product in glaucoma, including the Phase 2 study conducted in patients with normal tension glaucoma.
Timolol/dorzolamide combination is in Phase 2 development for glaucoma. One Phase 2 trial has been completed, and no active trials are currently listed. The program remains investigational and is not described as approved by the FDA for any indication.
The timolol/dorzolamide combination has been studied in one completed Phase 2 trial, NCT00832377, titled the COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161). That trial enrolled 37 participants aged 18 years and older of all sexes, was uncontrolled, and has completed.
Timolol/dorzolamide combination is a fixed combination product that contains timolol, and timolol maleate and timolol are the comparator names used for that beta-blocker component. The combination pairs timolol with dorzolamide, so it is not identical to timolol alone; it is a separate combination therapy studied in glaucoma.